Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 8Other hematologic neoplasm 7Myeloid 5Thoracic 4Head & Neck 3Gastrointestinal 3Breast 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Endocrine 1Dermatologic 1CNS 1

Conditions

Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pioglitazone × Endocrine × Clear all
NCT01655719 2017-10-26

Pioglitazone in Thyroid Cancers

University of Michigan

Phase 2 Completed
1 enrolled 6 charts
EndocrineHead & Neck

Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene

Data powered by HemOnc (CC BY 4.0) Colophon âš¡